Semra TİRYAKİ DEMİR, Derya ÜNAL, Müge OLGAÇ, Aslı GELİNCİK, Raif COŞKUN, Bahauddin ÇOLAKOĞLU, Suna BÜYÜKÖZTÜRK

Erişkin herediter anjiödem hastalarında danazol ile yapılan uzun dönem profilaksi tedavisine uyumun değerlendirilmesi: Gerçek bir yaşam çalışması

Amaç: Herediter anjioödem (HAÖ) hastalarında profilaktik

Anahtar Kelimeler:

Tedaviye uyum, Herediter anjioödem, Tedavi, Uzun dönem profilaksi, Danazol, Yan etkiler

Evaluating adherence to long-term prophylaxis treatment with danazol in adult hereditary angioedema patients: A real life study

Objective: To investigate the adherence to the prophylactic

Keywords:

Adherence to treatment, Hereditary angioedema, Management, Long-term prophylaxis, Danazol, Side effects,

PDF

___

1. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis and approach to treatment for angioedema: consesnsus report from the Hereditary Angioedema International Working Group. Allergy 2014;69:602-16. doi: 10.1111/all.12380
2. Zuraw BL. Hereditary angioedema. N Engl J Med 2008;359:1027-36. doi: 10.1056/NEJMcp0803977.
3. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005;139:379-94.
4. Zilberberg M, Jacobsen T, Tillotson G. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. Allergy Asthma Proc 2010;31:511-9. doi: 10.2500/ aap.2010.31.3403.
5. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, Lopez- Trascasa M. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevelance in Spain. Ann Allergy Asthma Immunol 2005;94:498-503.
6. Bygum A. Hereditary angioedema in Denmark: a nationwide survey. Br J Dermatol 2009;161:1153-8. doi: 10.1111/j.1365- 2133.2009.09366.x.
7. Craig T, Aygören-Pürsün E, Bork K, et al. WAO Guideline for the management of hereditary angioedema. World Allergy Organ J 2012;5:182-9. doi: 10.1097/ WOX.0b013e318279affa.
8. Caballero T, Baeza ML, Cabanas R, et al. Consensus statement on the diagnosis, management and the treatment of angioedema mediated by bradikynin. Part II. Treatment, follow up, and special situations. J Investig Allergol Clin Immunol 2011;21:422-41.
9. Costantino G, Casazza G, Bossi I, Duca P, Cicardi M. Longterm prophylaxis in hereditary angio-edema: a systematic review. BMJ Open 2012;2:e000524. doi: 10.1136/ bmjopen-2011-000524.
10. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE. Economic costs associated with acute attacks and long term management of hereditary angioedema. Ann Allergy Asthma Immunol 2010;104:314-20. doi: 10.1016/j. anai.2010.01.024.
11. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedem: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010;31:407-14. doi:10.2500/aap.2010.31.3394.
12. Nordenfelt P, Dawson S, Wahlgren CF, Lindfors A, Malbris L, Björkander J. Quantifying the burden of disease health state in patients with hereditary angiopedema in Sweeden. Allergy Asthma Proc 2014;35:185-90. doi: 10.2500/ aap.2014.35.3738.
13. Cabellero T, Aygören-Pürsün E, Bygum A, et al. The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe. Allergy Asthma Proc 2014;35:47-53. doi: 10.2500/aap.2013.34.3685.
14. Hughes DA, Bagust A, Haycox A, Walley T. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics 2001;19:1185-97.
15. Hudhes DA. Economic impact of poor compliance with pharmaceuticals. Expert Rev Pharmacoecon Outcomes Res 2002;2:327-35. doi: 10.1586/14737167.2.4.327
16. Bygum A, Fagerberg CR, Ponard D, Monnier N, Lunardi J, Drouet C. Mutational spectrum and phenotypesin Danish families with hereditary angioedema because of C1 inhibitor deficiency. Allergy 2011;66:76-84. doi: 10.1111/j.1398- 9995.2010.02456.x
17. Squeglia V, Barbarino A, Bova M, et al. High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study. Orphanet J Rare Dis 2016; 11:133.doi: 10.1186/s13023.016.0518-8.
18. Nordenfelt P, Nilsson M, Björkander J, Mallbris L, Lindfors A, Whalgren CF. Hereditary angioedema in Swedish adults: report from the national cohort. Acta Derm Venerol 2016;96:540-5. doi: 10.2340/00015.555.2274.
19. Gomez-Traseira C, Perez-Fernandez E, Lopez-Serrano MC, et al. Clinical pattern and acute and long-term management of hereditary angioedema due to C1-esterase inhibitor deficiency. J Investig Allergol Clin Immunol 2015;25:358- 64.
20. Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 2011;66:192-6. doi: 10.1111/j.1398-9995.2010.02433.x.
21. Ren HL, Zhang HY. Clinical features of hereditary angioedema: analysis of 133 cases. Zhonghua Yi Xue Za Zhi 2007;87:2772-6.
22. Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with Danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976;295:1444-8. doi: 10.1056/NEJM197.612.232952602.
23. Bork K, Bygum A, Hardt J. Benefits and risks of Danazol in hereditary angioedema: a long term survey of 118 patients. Ann Allergy Asthma Immunol 2008;100:153-61. doi: 10.1016/S1081-1206(10)60424-3.
24. Riedl MA. Critical appraisal of androgen use in hereditary angioedema: a systematic review. Ann Allergy Asthma Immunol 2015;114:281-8. doi: 10.1016/j.anai.2015.01.003.
25. Cicardi M, Suffritti C, Perego F, Caccia S. Novelties in the diagnosis and treatment of angioedema. J Investig Allergol Clin Immunol 2016;26:212-1. doi: 10.18176/jiaci.0087
26. Farkas H, Veszeli N, Csuka D, et al. Management of pregnancies in a hereditary angioedema patients after treatment with attenuated androgens since childhood. J Obstet Gynaecol 2015;35:89-90. doi: 10.3109/01443.615.2014.925860.
27. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363:513-22. doi: 10.1056/NEJMoa0805538.
28. Craig T, Shapiro R, Vegh A, et al. Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema. Allergy Rhinol (Providence). 2017:1:8:13-19. doi: 10.2500/ar.2017.8.0192
29. Ucar R, Arslan S, Baran M, Caliskaner AZ. Difficulties encountered in the emergency department by patients with hereditary angioedema experiencing acute attacks. Allergy Asthma Proc 2016;37:72-5. doi: 10.2500/aap.2016.37.3905.
30. Kesim B, Uyguner ZO, Gelincik A, et al. The Turkish hereditary angioedema pilot study (TURHAPS): the first Turkish series of hereditary angioedema. Int Arch Allergy Immunol 2011;156:443-50. doi:10.1159/000323915.
31. Zanichelli A, MagerlM, Longhurst H, Fabien V, Maurer M. Hereditary angioedema with C1 inhibitor deficiency: delay indiagnosis in Europe. Allergy Asthma Clin Immunol 2013;9:29. doi: 10.1186/1710-1492-9-29.
32. Frank MM, Gelfand JA, Atkinson JP. Herediatry angioedema: the clinical syndrome and its management. Ann Intern Med 1976;84:580-93.
33. Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitör deficiency workshop and beyond. J Allergy Clin Immunol 2004;114(3 Suppl):S51-131.
34. Agostoni A. Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992;71:206-15.
35. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006;119:267-74.